 FORT MYERS, FL ACCESSWIRE January 5, 2021 NeoGenomics, Inc. NASDAQ:NEO the Company, a leading provider of cancer-focused genetics testing services and global oncology contract research services, today announced that it has commenced proposed underwritten public offerings of approximately 200,000,000 of newly issued shares of common stock the common stock offering and 250,000,000 aggregate principal amount of convertible senior notes due 2028 the notes the notes offering. In addition, NeoGenomics expects to grant the underwriters of the offerings a 30-day option to purchase up to an additional a 30,000,000 of shares of its common stock at the public offering price, less underwriting discounts and commissions, and b 37,500,000 aggregate principal amount of the notes, less underwriting discounts and commissions and solely to cover over-allotments with respect to the notes offering. 